286 related articles for article (PubMed ID: 31324226)
41. Varicella-zoster virus clades circulating in Spain over two decades.
González I; Molina-Ortega A; Pérez-Romero P; Echevarría JE; He L; Tarragó D
J Clin Virol; 2019 Jan; 110():17-21. PubMed ID: 30517902
[TBL] [Abstract][Full Text] [Related]
42. Seroprevalence of varicella zoster antibodies among children with malnutrition, malignancies and HIV infection.
Admani B; Macharia WM; Were F
East Afr Med J; 2008 Oct; 85(10):480-6. PubMed ID: 19537424
[TBL] [Abstract][Full Text] [Related]
43. [Seroepidemiology of varicella among the healthy population aged 1-19 years in Harbin, China].
Li XK; Gao XL; Li Y; Xu H; Fan CL
Zhongguo Dang Dai Er Ke Za Zhi; 2019 Mar; 21(3):203-207. PubMed ID: 30907340
[TBL] [Abstract][Full Text] [Related]
44. [Characterization analysis of gM, gL genes of varicella zoster virus in six provinces of China].
Mou JJ; Qi MY; Li CS; Zheng HY; Chen M; Zhou JH; He JL; Xu WW; Xu ST; Xu XG
Zhonghua Yu Fang Yi Xue Za Zhi; 2018 Apr; 52(4):419-423. PubMed ID: 29614611
[No Abstract] [Full Text] [Related]
45. Molecular characterisation of varicella-zoster virus strains in Germany and differentiation from the Oka vaccine strain.
Sauerbrei A; Eichhorn U; Gawellek S; Egerer R; Schacke M; Wutzler P
J Med Virol; 2003 Oct; 71(2):313-9. PubMed ID: 12938208
[TBL] [Abstract][Full Text] [Related]
46. Cellular immune response of a varicella vaccine following simultaneous DTaP and VZV vaccination.
Habermehl P; Lignitz A; Knuf M; Schmitt HJ; Slaoui M; Zepp F
Vaccine; 1999 Feb; 17(7-8):669-74. PubMed ID: 10067672
[TBL] [Abstract][Full Text] [Related]
47. Prevalence of IgG varicella zoster virus antibodies in the Kuikuro and Kaiabi indigenous communities in Xingu National Park, Brazil, before varicella vaccination.
Lafer MM; de Moraes-Pinto MI; Weckx LY
Rev Inst Med Trop Sao Paulo; 2005; 47(3):139-42. PubMed ID: 16021286
[TBL] [Abstract][Full Text] [Related]
48. Seroepidemiology of varicella-zoster in Pakistan.
Akram DS; Qureshi H; Mahmud A; Khan AA; Kundi Z; Shafi S; N-ur-Rehman ; Olowokure B; Weil J; Bock H; Yazdani I
Southeast Asian J Trop Med Public Health; 2000 Dec; 31(4):646-9. PubMed ID: 11414405
[TBL] [Abstract][Full Text] [Related]
49. [Varicella-zoster virus seroprevalence in nursery and day-care workers in Lyon (France)].
Reignier F; Romanò L; Thiry N; Beutels P; Van Damme P; Fau C; Gaspard C; Mamoux V; Zanetti A; Floret D
Med Mal Infect; 2005 Apr; 35(4):192-6. PubMed ID: 15914287
[TBL] [Abstract][Full Text] [Related]
50. Varicella zoster virus immunity in multinational health care workers of a Saudi Arabian hospital.
Almuneef M; Dillon J; Abbas MF; Memish Z
Am J Infect Control; 2003 Oct; 31(6):375-81. PubMed ID: 14608306
[TBL] [Abstract][Full Text] [Related]
51. Estimation of age-specific rates of reactivation and immune boosting of the varicella zoster virus.
Marinelli I; van Lier A; de Melker H; Pugliese A; van Boven M
Epidemics; 2017 Jun; 19():1-12. PubMed ID: 28007549
[TBL] [Abstract][Full Text] [Related]
52. How reliable is the history of chickenpox? Varicella serology among children up to 14 years of age.
Kavaliotis J; Petridou S; Karabaxoglou D
Int J Infect Dis; 2003 Dec; 7(4):274-7. PubMed ID: 14656418
[TBL] [Abstract][Full Text] [Related]
53. One single-center cross-sectional investigation on varicella antibody level of all age groups in Chinese people.
Meng QH; Cheng XP; Liu DD; Chen CH; Yao KH
Hum Vaccin Immunother; 2021 Feb; 17(2):358-362. PubMed ID: 32966147
[TBL] [Abstract][Full Text] [Related]
54. Seroprevalence rates in children aged 3-6 years after implementing a two-dose varicella vaccination: A observational study.
Zhang Z; Zhang Y; Yu J; Dong C; Zhang J; Liu N; Qian C; Luan L
Hum Vaccin Immunother; 2023 Dec; 19(1):2211465. PubMed ID: 37203320
[TBL] [Abstract][Full Text] [Related]
55. Seroepidemiology of varicella-zoster virus in Korean adolescents and adults using fluorescent antibody to membrane antigen test.
Han SB; Kang KR; Huh DH; Lee HC; Kim JH; Kang JH; Ma SH
Epidemiol Infect; 2015 Jun; 143(8):1643-50. PubMed ID: 25234331
[TBL] [Abstract][Full Text] [Related]
56. [An investigation on serum antibody level of varicella-zoster virus in healthy population in Beijing].
Suo LD; Zhao D; Chen M; Li J; Dong M; Wang YT; Yu XL; Li MZ; Huang F; Pang XH; Lu L
Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Feb; 56(2):108-113. PubMed ID: 35184436
[No Abstract] [Full Text] [Related]
57. Seroprevalence survey for Varicella among healthcare workers and medical students in Italy.
Balbi O; Baldi S; Rizza S; Pietroiusti A; Perrone S; Coppeta L
Hum Vaccin Immunother; 2021 Feb; 17(2):372-376. PubMed ID: 32643520
[TBL] [Abstract][Full Text] [Related]
58. Effectiveness of live varicella vaccine.
Takahashi M
Expert Opin Biol Ther; 2004 Feb; 4(2):199-216. PubMed ID: 14998778
[TBL] [Abstract][Full Text] [Related]
59. Seroepidemiology of varicella zoster virus infection in Vojvodina, Serbia.
Medić S; Petrović V; Milosević V; Lozanov-Crvenković Z; Brkić S; Andrews N; de Ory F; Anastassopoulou C
Epidemiol Infect; 2018 Sep; 146(12):1593-1601. PubMed ID: 29909816
[TBL] [Abstract][Full Text] [Related]
60. Seropositivity of Varicella zoster virus in vaccinated Korean children and MAV vaccine group.
Choi UY; Huh DH; Kim JH; Kang JH
Hum Vaccin Immunother; 2016 Oct; 12(10):2560-2564. PubMed ID: 27484734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
